Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Trial Parameters
Brief Summary
Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.
Eligibility Criteria
Inclusion Criteria: 1. Patient aged 18 and over. 2. Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01/11/2023: 1. Progressive, metastatic, castration-resistant prostate cancer, 2. overexpressing prostate specific membrane antigen (PSMA) 3. treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone). 3. Patient able to lie still for 1 hour for image acquisition. 4. Patient's place of residence \< 2 hours' drive from the Institut Bergonié. 5. Patient has not expressed any opposition to the use of his/her medical data for research purposes. Exclusion Criteria: None